SCHEMBL6420147

SCHEMBL6420147

C=CCn1nccc1C(=O)c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
CXCL8 P10145 1/20 0.40
AKR1B1 P15121 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
GLO1 Q04760 1/20 0.40
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
HPGD P15428 3/20 0.39
SRD5A2 P31213 2/20 0.39
HSP90AA1 P07900 2/20 0.38
MAPT P10636 2/20 0.38
MITF O75030 1/20 0.38
MAPK1 P28482 1/20 0.38
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2718697 0.83 THRB (0.49) HTTALDH1A1LMNANPC1RAB9A
SCHEMBL2401146 0.73 PPARG (0.52) HTTALDH1A1LMNACXCL8AKR1B1
SCHEMBL2719494 0.71 PPARG (0.51) ALDH1A1LMNANPC1RAB9ARXFP1
SCHEMBL2977171 0.70 ELANE (0.46) HTTLMNANPC1RAB9ARXFP1
SCHEMBL6158697 0.70
SCHEMBL6421973 0.70 CYP3A4 (0.39) ALDH1A1LMNANPC1RAB9AMAPT
SCHEMBL2978805 0.70 ALDH1A1 (0.42) HTTALDH1A1LMNANPC1RAB9A
SCHEMBL2717097 0.69 ALDH1A1 (0.48) HTTALDH1A1LMNAAKR1B1NPC1
SCHEMBL1367696 0.67
SCHEMBL8329694 0.66 ALDH1A1 (0.59) HTTALDH1A1LMNAPTGS1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 US disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 HTT 4800/4885ALDH1A1 476/4885LMNA 4536/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 HTT 4182/4885ALDH1A1 603/4885LMNA 4453/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 HTT 4291/4885ALDH1A1 530/4885LMNA 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.